[DOI] [PubMed] [Google Scholar] 25.Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM
A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinsons disease by reducing chronic inflammation in the brain
Criteria typically include: [2] Age 18+ with obesity No history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (personal or family) Diagnosed severe sleep apnea (excluding central or complex apnea) Sleep study within past 3 years documenting AHI score (apnea-hypopnea index, measuring sleep apnea severity) Currently following a diet and exercise program Tried preferred alternatives or have documented allergies/contraindications If you suspect you have OSA (snoring, daytime fatigue, witnessed breathing pauses), ask your Kaiser PCP for a sleep study referral
Maintaining a healthy diet is the best way to maximize semaglutide medication's benefit
The phase 2 study specifically measured cravings and found significant reductions in desire for sweet foods (as early as week 4), salty foods (by week 16), and fatty foods (by weeks 12-16) at doses of 4mg and above compared to placebo
